Joseph A. DiGuiseppi

Joseph A. DiGuiseppi

Auto-generated profile, based on publicly available information

Joseph A. DiGuiseppi

Department of Biomedical Sciences, School of Medicine, Creighton University, Omaha, NE 68178, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Science Advances
Verified
Journal Article
Open access
SVSarath Vijayakumar
Sarath Vijayakumar
JDJoseph A. DiGuiseppi
Joseph A. DiGuiseppi
PDParinaz Jila Dabestani
Parinaz Jila Dabestani
WRWilliam Ryan
William Ryan
RQRene Vielman Quevedo
Rene Vielman Quevedo
JZJian Zuo
Jian Zuo
Noise-induced hearing loss (NIHL) is a common sensorineural hearing impairment that lacks U.S. Food and Drug Administration–approved drugs. To fill the gap in effective screening models, we used an in silico transcriptome-based drug screening approach, identifying 22 biological pathways and 64 potential small molecule treatments for NIHL. Two of these, afatinib and zorifertinib [epidermal growth factor receptor (EGFR) inhibitors], showed efficacy in zebrafish and mouse models. Further tests with EGFR knockout mice and EGF-morpholino zebrafish confirmed their protective role against NIHL. Molecular studies in mice highlighted EGFR’s crucial involvement in NIHL and the protective effect of zorifertinib. When given orally, zorifertinib was found in the perilymph with favorable pharmacokinetics. In addition, zorifertinib combined with AZD5438 (a cyclin-dependent kinase 2 inhibitor) synergistically prevented NIHL in zebrafish. Our results underscore the potential for in silico transcriptome-based drug screening in diseases lacking efficient models and suggest EGFR inhibitors as potential treatments for NIHL, meriting clinical trials.

26 February 2019 in Neuroscience Letters
Verified
Journal Article
Closed access
JDJoseph DiGuiseppi
Joseph DiGuiseppi
JZJian-Min Zuo
Jian-Min Zuo